Kymera Therapeutics (KYMR) Total Current Liabilities (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Total Current Liabilities of $62.6 million for Q1 2026, up 6.19% year-over-year from $59.0 million in Q1 2025, and down 24.72% quarter-over-quarter from $83.2 million in Q4 2025.
Kymera Therapeutics (KYMR) Total Current Liabilities (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Total Current Liabilities for 8 consecutive years, with $62.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 6.19% year-over-year to $62.6 million; the TTM figure through Mar 2026 stood at $62.6 million (up 6.19% YoY), while the FY2025 annual figure was $83.2 million, up 22.79% from the prior year.
- Total Current Liabilities declined to $62.6 million in Q1 2026 per KYMR's latest filing, from $83.2 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $91.1 million in Q3 2022 and bottomed at $54.6 million in Q2 2023.
- Historically, Total Current Liabilities has averaged $71.8 million across 5 years, with a median of $67.8 million in 2024.
- Annual changes were most pronounced in 2023 — Total Current Liabilities plunged 37.6% — and 2025, when it jumped 40.87%.
- Kymera Therapeutics' Total Current Liabilities stood at $71.3 million in 2022, then gained by 20.11% to $85.7 million in 2023, then decreased by 20.92% to $67.8 million in 2024, then advanced by 22.79% to $83.2 million in 2025, then decreased by 24.72% to $62.6 million in 2026.
- Business Quant data shows KYMR's Total Current Liabilities at $62.6 million in Q1 2026, $83.2 million in Q4 2025, and $71.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | 71.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 71.33 Mn |
| Mar 31, 2026 | 62.64 Mn |
| Dec 31, 2025 | 83.21 Mn |
| Sep 30, 2025 | 71.58 Mn |
| Jun 30, 2025 | 87.54 Mn |
| Mar 31, 2025 | 58.99 Mn |
| Dec 31, 2024 | 67.77 Mn |
| Sep 30, 2024 | 66.53 Mn |
| Jun 30, 2024 | 62.14 Mn |
| Mar 31, 2024 | 56.14 Mn |
| Dec 31, 2023 | 85.69 Mn |
| Sep 30, 2023 | 63.17 Mn |
| Jun 30, 2023 | 54.60 Mn |
| Mar 31, 2023 | 61.93 Mn |
| Dec 31, 2022 | 71.34 Mn |
| Sep 30, 2022 | 91.12 Mn |
| Jun 30, 2022 | 87.50 Mn |
| Mar 31, 2022 | 88.34 Mn |
| Dec 31, 2021 | 92.54 Mn |
| Sep 30, 2021 | 94.49 Mn |